The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Isocarboxazid in the treatment of depression

Published Online:https://doi.org/10.1176/ajp.140.6.792

Of 50 outpatients with nonpsychotic, nonmelancholic, anxious depression, the 24 patients taking isocarboxazid had better scores on all outcome measures than the 26 patients taking placebo. Differences on several variables reached statistical significance by weeks 4-6.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.